Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Revenue

In the year 2025, Tibet Rhodiola Pharmaceutical Holding Co. had annual revenue of 2.98B CNY with 6.23% growth. Tibet Rhodiola Pharmaceutical Holding Co. had revenue of 892.27M in the quarter ending December 31, 2025, with 41.34% growth.

• Revenue: 2.98B
• Revenue Growth: +6.23%
• P/S Ratio: 4.77
• Revenue / Employee: 5.00M
• Employees: 596
• Market Cap: 14.22B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.98B	174.82M	6.23%
Dec 31, 2024	2.81B	-327.62M	-10.45%
Dec 31, 2023	3.13B	579.72M	22.69%
Dec 31, 2022	2.55B	416.02M	19.45%
Dec 31, 2021	2.14B	765.48M	55.75%